摘要
目的探讨甲磺酸阿帕替尼联合卡瑞利珠单抗治疗Ⅲ/Ⅳ期胃癌的效果及对无进展生存期(PFS)的影响。方法选取86例Ⅲ/Ⅳ期胃癌患者,按照随机数字表法分为观察组和对照组各43例,两组均进行放化疗,其中对照组同步采用甲磺酸阿帕替尼治疗,观察组在对照组基础上联合卡瑞利珠单抗治疗,随访1年,观察两组近期疗效、氧化应激反应、PFS及不良反应。结果治疗后观察组近期有效率高于对照组(P<0.05);治疗后两组GSH-PX、SOD均升高,MDA均下降,且观察组GSH-PX、SOD均高于对照组,MDA低于对照组(P<0.05);随访1年,观察组PFS、无进展生存率均高于对照组(P<0.05);两组发生肝功能损伤、胃肠道反应、骨髓抑制、蛋白尿等不良反应严重程度无显著差异(P>0.05)。结论甲磺酸阿帕替尼联合卡瑞利珠单抗治疗Ⅲ/Ⅳ期胃癌较单独使用甲磺酸阿帕替尼能有效改善近期疗效,降低氧化应激反应,延长无进展生存时间,是一种安全有效的治疗方法。
Objective To explore the clinical efficacy and progression-free survival(PFS)time of apatinib mesylate combined with camrelizumab in the treatment of stageⅢ~Ⅳgastric cancer.Methods 86 patients with stageⅢ~Ⅳgastric cancer were selected,and divided into 2 groups using random number table methods,each with 43 cases.Both groups received radiochemotherapy,based on this,the control group received apatinib mesylate tablets,and the observation group received apatinib mesylate combined with camrelizumab.A one-year follow-up was conducted to observe the short-term efficacy,oxidative stress response,PFS and adverse reactions.Results The short-term effective rate of the observation group was higher than that of the control group(P<0.05).After treatment,an increase in glutathione peroxidase(GSH-Px)and superoxide dismutase(SOD)along with a decrease in malondialdehyde(MDA)were found in both groups,and the observation group had significantly larger GSH-PX and SOD values,and smaller MDA values compared with the control group,with statistical difference(all P<0.05).During the 1-year follow-up,the PFS time and rate of observation group were higher than those of control group(P<0.05).The severity of adverse reactions such as hepatic impairment,gastrointestinal reactions,bone marrow suppression and proteinuria had no statistical difference between the 2 groups(P>0.05).Conclusion Compared with apatinib mesylate treatment alone,its combination with camrelizumab in the treatment of stageⅢ~Ⅳgastric cancer achieves better short-term efficacy in terms of milder oxidative stress and longer PFS time.
作者
梁丽君
LIANG Lijun(The First Affiliated Hospital of Henan Science and Technology University,Luoyang,471000)
出处
《实用癌症杂志》
2022年第5期851-854,共4页
The Practical Journal of Cancer
基金
河南省医学科技攻关计划联合共建(编号:LHGJ20190629)。
